Market Cap 76.56M
Revenue (ttm) 200,000.00
Net Income (ttm) -26.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,085.00%
Debt to Equity Ratio -0.21
Volume 436,100
Avg Vol 580,102
Day's Range N/A - N/A
Shares Out 11.78M
Stochastic %K 27%
Beta 0.89
Analysts Strong Sell
Price Target $30.71

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 801 676 9695
Website: clene.com
Address:
6550 South Millrock Drive, Suite G50, Salt Lake City, United States
Fidia
Fidia May. 13 at 11:50 AM
$CLNN The news regarding the Type C meeting has fundamentally shifted the company's valuation, but many-aside from those who've truly analyzed CLNN--fail to realize its significance. On the day of the announcement, we likely saw an influx of momentum traders looking for a quick pump, many of whom have since left out of boredom. That's just the nature of short-term players, We could see a sudden price spike for no apparent reason; remember, the stock hit $13 on thin volume last year. The major difference now is that our outlook is much stronger this vear than last, and next year looks even more promising. Buying in at a lower price than the VCs and holding firm is the only thing we need to do.
1 · Reply
Takeover24
Takeover24 May. 13 at 2:09 AM
$CLNN https://invest.clene.com/node/12631/html This new 13G strongly suggests that Vivo was the sole buyer of the May $7M offering. If so, that is VERY significant. Vivo is not a tourist trader — they are a sophisticated long-term biotech investor already deeply involved in the story through prior financings. Instead of walking away after years of volatility, they now appear to be doubling down ahead of NDA submission and potential AA discussions. Also important, the May raise was straight common stock at $7 with no warrants attached. That is the opposite of toxic financing behavior and should make everyone feel better about Chidozie's selling (which we all deduce is for reasons unrelated to the underlying fundamentals of the company or belief in the science etc).
1 · Reply
prusio1
prusio1 May. 13 at 2:08 AM
$CLNN forgot to link it. https://invest.clene.com/node/12631/html
0 · Reply
prusio1
prusio1 May. 13 at 2:08 AM
$CLNN CLNN just filed 13G. Vivo Capital is a well-known healthcare/life sciences investment firm that specializes in biotech and growth-stage healthcare companies. That matters because these are not random retail investors. The filing shows they still maintain exposure through common stock, Series A warrants, Series B warrants, older 2023 tranche warrants. That suggests that they still see enough potential upside to maintain the position structure. Before the FDA meeting, many investors questioned whether CLNN even had a credible regulatory path. After the meeting the probability distribution changed. Now there is at least a plausible path toward NDA submission, filing acceptance, possible accelerated approval. That makes warrants potentially much more valuable. So this filing becomes more meaningful in context.
0 · Reply
paule815
paule815 May. 13 at 1:07 AM
$CLNN just go to $100
0 · Reply
Cresskill198
Cresskill198 May. 12 at 8:47 PM
$CLNN fyi
0 · Reply
Mulhollandr
Mulhollandr May. 12 at 8:09 PM
$CLNN cmon give us a fat form 4 today! Don’t make us wait till tomorrow chidozie!
0 · Reply
Verudoxi
Verudoxi May. 12 at 7:24 PM
$CLNN Personally, I think very highly of CLNN. 🚀 However, it's completely unpredictable in the short term. 📉📈 How much cash on hand do you think CLNN will have by August 2026 (median value)? 🤔 Also, when do you expect Chidozie’s Form 4 filings to come to an end? Clearly, the CLNN narrative has become even stronger since the last meeting minutes, but it seems like the market might keep ignoring it due to the fear of dilution. 😨 From a long-term perspective, I still believe this is a great entry point, but honestly, I have no clue how it'll play out in the short run. 🤷‍♂
1 · Reply
Mulhollandr
Mulhollandr May. 12 at 7:19 PM
$CLNN maybe he’s done for the day? Done for good? Or about to drop the hammer on one more big block sale?🤔
1 · Reply
Sabby_Management
Sabby_Management May. 12 at 6:46 PM
$CLNN lol shorting this turd like chode-ozie. Let me get cheaper shares.
0 · Reply
Latest News on CLNN
Clene price target raised to $50 from $48 at Canaccord

2026-05-08T11:23:32.000Z - 5 days ago

Clene price target raised to $50 from $48 at Canaccord


Clene Transcript: Emerging Growth Conference 92

May 6, 2026, 3:25 PM EDT - 6 days ago

Clene Transcript: Emerging Growth Conference 92


Clene to Present at Upcoming May Conferences

May 5, 2026, 8:00 AM EDT - 8 days ago

Clene to Present at Upcoming May Conferences


Clene reports FY25 EPS ($2.65), consensus ($2.35)

2026-03-12T12:12:18.000Z - 2 months ago

Clene reports FY25 EPS ($2.65), consensus ($2.35)


Clene Transcript: Emerging Growth Virtual Conference

Feb 25, 2026, 1:45 PM EST - 2 months ago

Clene Transcript: Emerging Growth Virtual Conference


Clene issues letter to shareholders on CNM-Au8 2026 catalysts

2026-02-24T13:13:07.000Z - 2 months ago

Clene issues letter to shareholders on CNM-Au8 2026 catalysts


Clene to Present at the Emerging Growth Conference

Feb 19, 2026, 8:30 AM EST - 2 months ago

Clene to Present at the Emerging Growth Conference


Clene Transcript: Emerging Growth Conference 89

Jan 21, 2026, 3:10 PM EST - 3 months ago

Clene Transcript: Emerging Growth Conference 89


Clene announces over $28M registered direct offering

2026-01-09T13:41:01.000Z - 4 months ago

Clene announces over $28M registered direct offering


Clene Announces Registered Direct Offering of Over $28 Million

Jan 9, 2026, 8:30 AM EST - 4 months ago

Clene Announces Registered Direct Offering of Over $28 Million


Clene Transcript: Emerging Growth Conference 88

Dec 10, 2025, 4:25 PM EST - 5 months ago

Clene Transcript: Emerging Growth Conference 88


Clene price target raised to $30 from $20 at Maxim

2025-12-03T18:15:36.000Z - 5 months ago

Clene price target raised to $30 from $20 at Maxim


Clene Transcript: Study Update

Dec 3, 2025, 8:30 AM EST - 5 months ago

Clene Transcript: Study Update


Clene to Provide CNM-Au8® ALS Program Update

Dec 2, 2025, 5:39 PM EST - 5 months ago

Clene to Provide CNM-Au8® ALS Program Update


Clene reports Q3 EPS (85c), consensus (56c)

2025-11-13T13:10:28.000Z - 6 months ago

Clene reports Q3 EPS (85c), consensus (56c)


Clene sees cash runway into 2Q26

2025-11-13T13:10:16.000Z - 6 months ago

Clene sees cash runway into 2Q26


Clene Transcript: Emerging Growth Conference

Oct 23, 2025, 3:10 PM EDT - 7 months ago

Clene Transcript: Emerging Growth Conference


Clene announces presentation of combined REPAIR-MS results

2025-09-25T12:10:32.000Z - 8 months ago

Clene announces presentation of combined REPAIR-MS results


Clene price target lowered to $31 from $33 at Benchmark

2025-09-10T12:00:43.000Z - 8 months ago

Clene price target lowered to $31 from $33 at Benchmark


Clene files to sell 491,496 shares of common stock for holders

2025-09-05T20:20:08.000Z - 8 months ago

Clene files to sell 491,496 shares of common stock for holders


Clene Transcript: Emerging Growth Conference 85

Aug 20, 2025, 2:20 PM EDT - 9 months ago

Clene Transcript: Emerging Growth Conference 85


Clene price target lowered to $48 from $83 at Canaccord

2025-08-18T10:40:11.000Z - 9 months ago

Clene price target lowered to $48 from $83 at Canaccord


Clene reports Q2 EPS (78c) vs ($1.06) last year

2025-08-14T12:45:43.000Z - 9 months ago

Clene reports Q2 EPS (78c) vs ($1.06) last year


Clene to Present at the Canaccord 45th Annual Growth Conference

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference


Clene Transcript: Emerging Growth Conference 84

Jul 17, 2025, 3:10 PM EDT - 10 months ago

Clene Transcript: Emerging Growth Conference 84


Clene provides regulatory update following FDA Type C meeting

2025-06-30T14:38:15.000Z - 11 months ago

Clene provides regulatory update following FDA Type C meeting


Clene Transcript: Q2 Virtual Investor Summit Event

Jun 10, 2025, 1:00 PM EDT - 1 year ago

Clene Transcript: Q2 Virtual Investor Summit Event


Clene management to meet with Maxim

2025-06-03T17:30:17.000Z - 1 year ago

Clene management to meet with Maxim


Clene Transcript: Emerging Growth Conference 82

May 21, 2025, 3:10 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 82


Clene reports Q1 EPS (9c), consensus (78c)

2025-05-07T12:18:01.000Z - 1 year ago

Clene reports Q1 EPS (9c), consensus (78c)


Clene Transcript: 37th Annual ROTH Conference

Mar 18, 2025, 12:30 PM EDT - 1 year ago

Clene Transcript: 37th Annual ROTH Conference


Clene to Present at the 37TH Annual Roth Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Clene to Present at the 37TH Annual Roth Conference


Clene Announces 1-for-20 Reverse Stock Split

Jul 9, 2024, 8:00 AM EDT - 2 years ago

Clene Announces 1-for-20 Reverse Stock Split


Fidia
Fidia May. 13 at 11:50 AM
$CLNN The news regarding the Type C meeting has fundamentally shifted the company's valuation, but many-aside from those who've truly analyzed CLNN--fail to realize its significance. On the day of the announcement, we likely saw an influx of momentum traders looking for a quick pump, many of whom have since left out of boredom. That's just the nature of short-term players, We could see a sudden price spike for no apparent reason; remember, the stock hit $13 on thin volume last year. The major difference now is that our outlook is much stronger this vear than last, and next year looks even more promising. Buying in at a lower price than the VCs and holding firm is the only thing we need to do.
1 · Reply
Takeover24
Takeover24 May. 13 at 2:09 AM
$CLNN https://invest.clene.com/node/12631/html This new 13G strongly suggests that Vivo was the sole buyer of the May $7M offering. If so, that is VERY significant. Vivo is not a tourist trader — they are a sophisticated long-term biotech investor already deeply involved in the story through prior financings. Instead of walking away after years of volatility, they now appear to be doubling down ahead of NDA submission and potential AA discussions. Also important, the May raise was straight common stock at $7 with no warrants attached. That is the opposite of toxic financing behavior and should make everyone feel better about Chidozie's selling (which we all deduce is for reasons unrelated to the underlying fundamentals of the company or belief in the science etc).
1 · Reply
prusio1
prusio1 May. 13 at 2:08 AM
$CLNN forgot to link it. https://invest.clene.com/node/12631/html
0 · Reply
prusio1
prusio1 May. 13 at 2:08 AM
$CLNN CLNN just filed 13G. Vivo Capital is a well-known healthcare/life sciences investment firm that specializes in biotech and growth-stage healthcare companies. That matters because these are not random retail investors. The filing shows they still maintain exposure through common stock, Series A warrants, Series B warrants, older 2023 tranche warrants. That suggests that they still see enough potential upside to maintain the position structure. Before the FDA meeting, many investors questioned whether CLNN even had a credible regulatory path. After the meeting the probability distribution changed. Now there is at least a plausible path toward NDA submission, filing acceptance, possible accelerated approval. That makes warrants potentially much more valuable. So this filing becomes more meaningful in context.
0 · Reply
paule815
paule815 May. 13 at 1:07 AM
$CLNN just go to $100
0 · Reply
Cresskill198
Cresskill198 May. 12 at 8:47 PM
$CLNN fyi
0 · Reply
Mulhollandr
Mulhollandr May. 12 at 8:09 PM
$CLNN cmon give us a fat form 4 today! Don’t make us wait till tomorrow chidozie!
0 · Reply
Verudoxi
Verudoxi May. 12 at 7:24 PM
$CLNN Personally, I think very highly of CLNN. 🚀 However, it's completely unpredictable in the short term. 📉📈 How much cash on hand do you think CLNN will have by August 2026 (median value)? 🤔 Also, when do you expect Chidozie’s Form 4 filings to come to an end? Clearly, the CLNN narrative has become even stronger since the last meeting minutes, but it seems like the market might keep ignoring it due to the fear of dilution. 😨 From a long-term perspective, I still believe this is a great entry point, but honestly, I have no clue how it'll play out in the short run. 🤷‍♂
1 · Reply
Mulhollandr
Mulhollandr May. 12 at 7:19 PM
$CLNN maybe he’s done for the day? Done for good? Or about to drop the hammer on one more big block sale?🤔
1 · Reply
Sabby_Management
Sabby_Management May. 12 at 6:46 PM
$CLNN lol shorting this turd like chode-ozie. Let me get cheaper shares.
0 · Reply
Woodman7
Woodman7 May. 12 at 6:38 PM
$CLNN - 300,000 shares traded so far today…
1 · Reply
CLW092
CLW092 May. 12 at 5:39 PM
$CLNN Should this be cause for concern? Hold or Sell? Newbie over here. 😌
1 · Reply
neuroinvestor3
neuroinvestor3 May. 12 at 3:34 PM
$CLNN WTF.
3 · Reply
Cresskill198
Cresskill198 May. 12 at 1:28 PM
$CLNN Since this stock still hasn’t been widely discovered by institutional investors, retail trading is having a major impact on both sentiment and price action. Are you guys buying/adding here or selling? Personally, I’ll be accumulating slowly over the next few weeks — not aggressively, but steadily — until Chidozi finishes selling. From what I understand, he already completed his scheduled selling, but still has around 200k shares remaining. In my opinion, if he hadn’t been dumping shares into the market, this stock would likely already be trading above $10 by now. His continued selling pressure has clearly weighed on momentum and sentiment. That said, this could actually be a good opportunity to gradually absorb those shares because once that overhang is gone, the float becomes extremely thin, making it much harder to accumulate at these price levels. I’m looking at this period through the end of May as an opportunity to build a position slowly. what do you guys think?
3 · Reply
Woodman7
Woodman7 May. 12 at 11:12 AM
$CLNN - question for the board: How soon would you predict Clene will submit the NDA to the FDA? 3Q, so during June, July or August? I assume they would announce when it has been submitted??
2 · Reply
neuroinvestor3
neuroinvestor3 May. 12 at 2:17 AM
$CLNN Can we explain the Clene haters as not understanding the science, bitter that NurOwn isn't going anywhere, or that they are being paid by big pharma who stand to potentially lose a little market share on approval for MS? Or a combo of these options?
2 · Reply
neuroinvestor3
neuroinvestor3 May. 12 at 1:33 AM
$CLNN If I were a biotech analyst and saw what Chidozie (a former Board member) was doing, I'd probably be hesitant to issue or reiterate a "buy" rating... he's really F#$%#$ us over.... It's sad.
3 · Reply
Cresskill198
Cresskill198 May. 11 at 11:46 PM
$CLNN $CLNN The recent FDA Type C meeting could be a major turning point for Clene. Investors should pay attention to the FDA’s actual wording. The FDA stated Clene’s “proposed data may be capable of supporting the submission and review of an NDA under the accelerated approval pathway” for ALS. That is very encouraging language for a microcap biotech. The FDA also said NfL “could potentially serve as a reasonably likely surrogate endpoint,” which is another important regulatory signal. And remember, CNM-Au8 is not just a single indication story. It’s a nanocrystal platform with broader potential across neurodegenerative diseases. If Clene successfully advances toward NDA submission, today’s valuation could eventually look extremely disconnected from the opportunity ahead. For an $85M market cap company, this materially changes the risk/reward profile in my opinion. The FDA is clearly discussing a possible path forward, not shutting the door.
0 · Reply
Ravery
Ravery May. 11 at 11:36 PM
$CLNN Chidozie has dominated too much of our time. It is my belief that he has sold his shares for strategic reasons and not because the stock is fundamentally flawed. However it has been a headwind for the stock. I assumed he would completely dissolve his position and it looks like he is either done or close to. If Mr. Market wants to continue to punish the shares because of the optics I will gladly add more. The fate of our investment will be in the hands of the fda soon. With that being said, it would be nice of someone else stepped up to buy shares like Matlin did in Jan. I hear a lot of enthusiastic talk from C-suite, but not a lot of financial commitment. Rob, buy some shares and turn the optics around.
1 · Reply
neuroinvestor3
neuroinvestor3 May. 11 at 10:41 PM
$CLNN ouch.. would have sucked to have bought at 7.70 today....
0 · Reply
7m3835d3
7m3835d3 May. 11 at 8:21 PM
$CLNN ok, this is good news. These are all of his remaining shares, he is done soon! https://invest.clene.com/static-files/c3d5909d-8194-4391-b72b-fed6def0f5b1
1 · Reply
Cresskill198
Cresskill198 May. 11 at 8:13 PM
$CLNN the stock is now on the SSR list. The best time to squeeze all day tomorrow.
0 · Reply